Vibegron

Vibegron is a prescription medication approved for the treatment of overactive bladder (OAB) symptoms in adults. It is a selective beta-3 adrenergic receptor agonist marketed under the brand name Gemtesa by Astellas Pharma. The drug is taken orally once daily, with or without food.

Mechanism of action: Vibegron activates beta-3 receptors in the detrusor smooth muscle, promoting relaxation of the bladder during the filling phase. This increases bladder capacity and helps reduce urgency, frequency, and urge incontinence.

Clinical use and approval: In the United States, vibegron received FDA approval in December 2020 for treatment of OAB symptoms. It is positioned as an alternative to antimuscarinic therapies and may be chosen for patients who prefer a beta-3–selective approach or who experience adverse effects with other treatments.

Safety and adverse effects: Vibegron is generally well tolerated. Common adverse events reported include urinary tract infection, nasopharyngitis, headache, and hypertension. Serious adverse events are uncommon; caution is advised in patients with uncontrolled hypertension or significant hepatic impairment, and patients should be monitored for blood pressure changes during treatment.

Regulatory status and availability: Brand name Gemtesa; approved in the United States and marketed by Astellas. Regulatory status varies by country, with additional approvals pursued or granted in other regions.

Research and future directions: Ongoing studies evaluate long-term safety, efficacy in broader patient populations, and comparisons with other therapies.